Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.

Journal Article

TAS-102 is a novel formulation of the fluorinated pyrimidine analogue trifluorothymidine (FTD) with an inhibitor of thymidine phosphorylase. The purpose of this study was to determine the MTD and DLT for TAS-102 administered three times a day on days 1-5 and 8-12 every 4 weeks. Fifteen patients were enrolled with two patients experiencing dose-limiting fatigue and granulocytopenia at the first dose level (80 mg/m2/day). Granulocytopenia was the primary toxicity: 7 patients experienced grade 3 or 4 granulocytopenia with the first course. No responses were noted, but nine patients demonstrated prolonged stable disease in this heavily pretreated 5-FU refractory population.

Full Text

Duke Authors

Cited Authors

  • Overman, MJ; Kopetz, S; Varadhachary, G; Fukushima, M; Kuwata, K; Mita, A; Wolff, RA; Hoff, P; Xiong, H; Abbruzzese, JL

Published Date

  • October 2008

Published In

Volume / Issue

  • 26 / 8

Start / End Page

  • 794 - 799

PubMed ID

  • 18798063

Electronic International Standard Serial Number (EISSN)

  • 1532-4192

International Standard Serial Number (ISSN)

  • 0735-7907

Digital Object Identifier (DOI)

  • 10.1080/07357900802087242

Language

  • eng